• 1
    Parkin DM,Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24 ( Suppl 3): S11S25.
  • 2
    Harper DM,Franco EL,Wheeler CM,Moscicki AB,Romanowski B,Roteli-Martins CM,Jenkins D,Schuind A,Costa Clemens SA,Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 124755.
  • 3
    Kleter B,van Doorn LJ,Schrauwen L,Molijn A,Sastrowijoto S,ter Schegget J,Lindeman J,ter Harmsel B,Burger M,Quint W. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 250817.
  • 4
    Castellsague X,Menendez C,Loscertales MP,Kornegay JR,dos SF,Gomez-Olive FX,Lloveras B,Abarca N,Vaz N,Barreto A,Bosch FX,Alonso P. Human papillomavirus genotypes in rural Mozambique. Lancet 2001; 358: 142930.
  • 5
    Kleter B,van Doorn LJ,ter Schegget J,Schrauwen L,van Krimpen K,Burger M,ter Harmsel B,Quint W. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998; 153: 17319.
  • 6
    Munoz N,Bosch FX,de Sanjose S,Herrero R,Castellsague X,Shah KV,Snijders PJ,Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 7
    Clifford G,Franceschi S,Diaz M,Munoz N,Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24 ( Suppl 3): S26S34.
  • 8
    Clifford GM,Gallus S,Herrero R,Munoz N,Snijders PJ,Vaccarella S,Anh PT,Ferreccio C,Hieu NT,Matos E,Molano M,Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 9918.
  • 9
    Menendez C,Castellsague X,Sacarlal J,Quintó Ll,Lloveras B,Klaustermeier J,Kornegay JR,Sigauque B,Bosch FX,Alonso PL. Prevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of Southern Mozambique. Clin Infect Dis, submitted.
  • 10
    Levi JE,Kleter B,Quint WG,Fink MC,Canto CL,Matsubara R,Linhares I,Segurado A,Vanderborght B,Neto JE,van Doorn LJ. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 2002; 40: 33415.
  • 11
    Naucler P,Da Costa FM,Ljungberg O,Bugalho A,Dillner J. Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 2004; 85 (Part 8): 218990.
  • 12
    Carrilho C,Gouveia P,Cantel M,Alberto M,Buane L,David L. Characterization of human papillomavirus infection, P53 and Ki-67 expression in cervix cancer of Mozambican women. Pathol Res Pract 2003; 199: 30311.
  • 13
    Carrilho C,Cirnes L,Alberto M,Buane L,Mendes N,David L. Distribution of HPV infection and tumour markers in cervical intraepithelial neoplasia from cone biopsies of Mozambican women. J Clin Pathol 2005; 58: 618.
  • 14
    Carrilho C. Cervical cancer in Mozambique: role of human papillomavirus (HPV) in the etiopathogenesis of cervix cancer and evaluation of the usefulness of some markers in the diagnosis, Doctoral Thesis, University of Oporto, Oporto, Portugal, 2005.
  • 15
    Bosch FX,Manos MM,Munoz N,Sherman M,Jansen AM,Peto J,Schiffman MH,Moreno V,Kurman R,Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796802.
  • 16
    Khan MJ,Castle PE,Lorincz AT,Wacholder S,Sherman M,Scott DR,Rush BB,Glass AG,Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 10729.